Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 2Thrombocythemia, Essential 1Small Cell Lung Carcinoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1GATA2 Deficiency 1Carcinoma, Neuroendocrine 1

Interventions

fludarabine 19Whole-Body Irradiation 18Cyclophosphamide 17fludarabine phosphate 16ruxolitinib 15Mycophenolic Acid 14Specimen Handling 13Tacrolimus 11Azacitidine 11Biopsy 10Peripheral Blood Stem Cell Transplantation 9Melphalan 9Cytarabine 9venetoclax 8Sirolimus 8Busulfan 8Stem Cell Transplantation 6Injections 6Granulocyte Colony-Stimulating Factor 6Daunorubicin 5Cyclosporine 5CPX-351 5luspatercept 4ivosidenib 4itacitinib 4fedratinib 4decitabine and cedazuridine drug combination 4Thiotepa 4Liposomes 4Cyclosporins 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × iadademstat × 1 year × Clear all
NCT06661915 2026-05-29

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

National Cancer Institute (NCI)

Phase 2 Suspended
62 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡